Canker Sore

Overview

Feature	Description
Definition	Recurrent Aphthous Stomatitis (RAS), commonly known as a canker sore, is a chronic, inflammatory condition characterized by the periodic development of round or oval, painful ulcers with a necrotic center, raised erythematous borders, usually confined to the non-keratinized oral mucosa.
Epidemiology	Prevalence: Very common, affecting approximately 5% to 25% of the general population worldwide, with reported rates as high as 60% in specific populations. Age: Usually begins in childhood or adolescence (peak incidence during the second decade of life). Sex: Slightly more common in females (F:M ratio ~1.4:1), though severity tends to be similar. Recurrence: Highly variable, ranging from episodes occurring once or twice yearly to near-constant presence.
Classification	Classified based on size, number, and healing time (Healing typically occurs without scarring).
Minor RAS (MiRAS)	Most common type (~80%). Ulcers are small (typically $\leq 5 \text{ mm}$ in diameter), shallow, single or multiple, heal within 10–14 days, and are not associated with scarring. Commonly found on the labial and buccal mucosa, and floor of the mouth.
Major RAS (MaRAS) (Sutton Disease)	Less common (~10%). Ulcers are larger ($>1 \text{ cm}$ in diameter), deeper, more painful, often last weeks to months (up to 6 weeks), and frequently heal with scarring. Can affect keratinized mucosa (e.g., hard palate, gingivae) but generally favor non-keratinized surfaces.
Herpetiform RAS (HuRAS)	Least common (~10%). Characterized by numerous (10–100), punctate, small ulcers ($\leq 3 \text{ mm}$) that often coalesce into larger, irregularly shaped lesions. Despite the name, this form is not caused by herpes simplex virus (HSV).

---

Pathophysiology

Category	Details
Mechanism	The exact etiology is unknown (idiopathic), but RAS is considered a multifactorial disease involving altered local immunity, genetics, and various environmental triggers. The predominant underlying mechanism is localized destruction of the oral epithelium mediated by cytotoxic T lymphocytes ($\text{CD8}^+$) (T-cell dysregulation model), leading to ulcer formation in response to an unidentified antigen. Elevated levels of pro-inflammatory cytokines (e.g., IL-2, IL-6, TNF-$\alpha$) are often observed.
Risk Factors	Genetic Predisposition: Strong genetic component; up to 40% of patients report a family history. Associations with specific HLA subtypes (e.g., HLA-B12, HLA-DRw9). Local Trauma: Minor mechanical injury (e.g., ill-fitting dentures, vigorous brushing, dental procedures). Nutritional Deficiencies: Iron, folate, Vitamin $\text{B}_{12}$, and zinc deficiencies (especially in severe or atypical cases). Systemic Diseases (Aphthosis-like): Behcet disease, systemic lupus erythematosus (SLE), inflammatory bowel disease (Crohn disease, ulcerative colitis), celiac disease, $\text{HIV}/\text{AIDS}$. Stress and Anxiety: Psychological stress is a documented trigger for recurrence. Hormonal Changes: Often exacerbated during the premenstrual period. Smoking Cessation: Paradoxically, cessation of smoking can trigger RAS in some cases. Pharmacological Agents: Rarely, NSAIDs, $\beta$-blockers, and certain chemotherapy agents.
Protective Factors	Smoking: Cigarette smokers have a significantly lower prevalence of RAS. Nicotine may induce hyperkeratinization which is thought to be protective, or it may modulate the immune response. Good Oral Hygiene: While excessive brushing can cause trauma, general good hygiene limits bacterial load.

---

Clinical Presentation

Signs and Symptoms

Feature	Characteristics
Cardinal Features	Pain: Disproportionate to the size of the lesion, often interfering with eating and speaking. Location: Non-keratinized mucosa (e.g., buccal and labial aspects, tongue, soft palate, floor of the mouth). Appearance: Well-circumscribed, round/oval ulcer with a shallow, gray-white/yellow pseudomembranous center, surrounded by a distinct, bright-red halo (erythematous rim).
Early Signs	Prodromal symptoms typically 1–2 days before ulceration: localized burning, tingling, itching, or a feeling of tautness in the affected area.
Advanced Signs	Ulceration is the advanced stage. In MaRAS, deep craters and extensive tissue destruction are seen; healing often takes $>$ 3 weeks and results in scarring.
Atypical Presentations	Multiple, recurring ulcers that are resistant to standard treatment; ulcers on keratinized mucosa (gingiva, hard palate); presence of systemic symptoms (fever, arthralgia, ocular inflammation, gastrointestinal symptoms), which suggests an underlying systemic disorder (e.g., Behcet disease).

Physical Examination

Examination	Findings
Inspection	Minor RAS: Single or a few small ulcers ($\leq 5 \text{ mm}$), non-indurated, shallow, characteristic central pseudomembrane and erythematous halo. Major RAS: Large, deep, crater-like ulcers ($>1 \text{ cm}$). Frequently located posteriorly in the oral cavity. Herpetiform RAS: Clusters of tiny pinhead ulcers that resemble vesicles (but are not), often coalescing. Ulcers are typically confined to the mouth (no associated perioral vesicles or lesions characteristic of HSV).
Palpation	Lesions are generally soft and non-indurated. Palpate regional lymph nodes: mild, transient cervical lymphadenopathy may be present, particularly with larger, secondarily infected ulcers. Significant lymphadenopathy should raise suspicion for another diagnosis.
Special Tests	None specific for primary RAS. Biopsy is usually unnecessary unless the lesion is chronic (>3 weeks) or atypical to rule out malignancy, fungal infection, or vesiculobullous disease.

---

Diagnostic Approach

History Taking

Questions	Rationale
Frequency and Duration	How often do the ulcers occur? How long do they last? Critical for confirming the recurrent nature of RAS.
Initial Presentation	When did the first episode occur? Helps assess the typical onset in adolescence/young adulthood.
Triggers	Ask about mechanical trauma, stress, specific foods (e.g., highly acidic, spicy, or sharp/crunchy foods), and menstrual cycle association.
Systemic Symptoms	Ask about fever, rash (especially acneiform or nodular), joint pain (arthritis/arthralgia), genital ulcers, and eye inflammation (uveitis, conjunctivitis). Essential for screening for Behcet disease.
Gastrointestinal Symptoms	Diarrhea, abdominal pain, or weight loss. Screen for IBD or Celiac disease.
Family History & Smoking Status	Genetic predisposition and protective/triggering effect of smoking.
Medications and Diet	Recent changes, use of NSAIDs, or assessment of nutritional intake.

Red Flags

• New onset of severe, refractory, or continuously present ulcers.
• Concomitant genital or ocular inflammation (Suggests Behcet disease).
• Presence of gastrointestinal symptoms, weight loss, or persistent diarrhea (Suggests IBD or Celiac disease).
• Ulcers that fail to heal within 3 weeks (Must rule out squamous cell carcinoma or other infectious causes).
• Systemic complaints (fever, fatigue, generalized lymphadenopathy).

Laboratory Tests

Laboratory investigation is not required for typical, self-limited RAS. Testing is reserved for patients with severe, persistent, or atypical presentation (especially $\text{MaRAS}$ or $\text{HuRAS}$) to rule out predisposing systemic causes.

Test Category	Indication & Detail
First-Line	Complete Blood Count (CBC): To check for anemia. Serum Ferritin, $\text{B}_{12}$, Folate Levels: To identify nutritional deficiencies. Antigliadin/Anti-transglutaminase Antibodies: If Celiac disease is suspected. $\text{HIV}$ Status: Consider if risk factors are present or if $\text{RAS}$ is unusually severe and refractory.
Confirmatory ($^\dagger$Indirect)	Tissue Biopsy: Only necessary to exclude other major diagnoses, such as squamous cell carcinoma, deep fungal infection, or primary vesiculobullous diseases (e.g., pemphigus, pemphigoid). Biopsy of RAS shows non-specific inflammation and ulceration.
Monitoring	Repetition of nutritional panel (Iron, $\text{B}_{12}$, Folate) if deficiency was identified, particularly following supplementation, to confirm correction.

Imaging

Imaging Type	Indication
Recommended	None, as RAS is a localized mucosal disorder.
Advanced	Rarely, upper and lower endoscopy or capsule endoscopy if significant gastrointestinal symptoms are present to confirm IBD or Celiac disease.

---

Management

Acute Management

The primary goal is pain relief, reduction of inflammation, and promotion of healing.

Intervention	Detail and Dosage
Immediate Pain Relief	Topical Anesthetics: 2% viscous lidocaine (swish and spit/swallow) applied PRN 15 minutes before meals. Oral Rinses: Diphenhydramine (Benadryl) elixir mixed 1:1 with Milk of Magnesia (a "magic mouthwash"). Use 5–10 $\text{mL}$ swished and held for several minutes, 4–6 times daily.
Inflammation Control (Topical)	Topical Corticosteroids (First-Line): Triamcinolone acetonide $0.1\%$ in dental paste (Kenalog in Orabase) applied 2–4 times/day, preferably after meals and before bed. Place a small dap and hold without rubbing. or Fluocinonide $0.05\%$ gel or ointment applied 2–4 times/day.
Stabilization	Avoid triggers (spicy/acidic foods, sharp trauma). Maintain excellent oral hygiene using a soft toothbrush and non-foaming toothpaste (some commercial foaming agents, specifically Sodium Lauryl Sulfate (SLS), may trigger $\text{RAS}$).
Emergency	Not applicable; $\text{RAS}$ is not a medical emergency, but severe pain interfering with hydration and nutrition may necessitate temporary systemic analgesia or potent topical therapy.

Chronic Management (For Recurrent or Major RAS)

Strategy	Pharmacological Detail and Dosage
Systemic Therapy (Reserved for severe, frequent, or Major RAS)	Colchicine: $0.6 \text{ mg}$ to $1.2 \text{ mg}$ once or twice daily. Useful due to its anti-inflammatory effects and microtubule inhibition. Thalidomide: Highly effective for refractory MaRAS, particularly in Behcet disease or $\text{HIV}/\text{AIDS}$-associated aphthae. DOSE: $50 \text{ mg}$ to $100 \text{ mg}$ daily at bedtime. Requires careful monitoring due to severe teratogenicity (mandatory use of $\text{REMS}$ program) and risk of peripheral neuropathy. Prednisone (Short Course): $20 \text{ mg}$ to $60 \text{ mg}$ daily, tapered over 5–7 days, for severe, acute outbreaks of MaRAS that impair function. Dapsone: $50 \text{ mg}$ to $100 \text{ mg}$ daily for refractory cases (monitor $\text{G6PD}$ status).
Non-pharmacological	Trigger Avoidance: Dietary modification (remove highly acidic/spicy foods, eliminate $\text{SLS}$ toothpaste). Stress Reduction: Counseling or relaxation techniques. Laceration Coverage: Use dental wax or intra-oral patches to shield lesions from trauma.
Monitoring	Monitor for treatment efficacy, side effects (especially with systemic agents like Colchicine, Thalidomide), and screen periodically for underlying systemic disease recurrence.

Treatment Algorithms

Level	Strategy	Therapeutic Focus
First-Line (Mild Minor RAS)	Topical Corticosteroids (Triamcinolone paste) AND Topical Anesthetics ("Magic Mouthwash" or lidocaine). Treat symptoms acutely as they arise.	Symptom control, reducing inflammation.
Second-Line (Frequent Minor or Mild Major RAS)	Topical Potent Steroids (Clobetasol $0.05\%$ gel/ointment) or Tetracycline Rinse: Tetracycline $250 \text{ mg}$ capsule dissolved in $5 \text{ mL}$ water, swished and spit 4 times daily (anti-inflammatory and secondary infection prevention).	Increase inflammatory suppression, reduce duration.
Refractory Cases (Severe or Major RAS)	Identify and correct nutritional deficiencies. Initiate Systemic Agents: Colchicine, Pentoxifylline, or in severe cases, Thalidomide or low-dose systemic Prednisone. Investigate thoroughly for underlying systemic disease (Behcet, IBD).	Immunomodulation, chronic prevention.

---

Complications

Type	Details
Common	Pain: Significant pain leading to difficulty eating, drinking, and speaking, resulting in poor nutritional status and weight loss (especially MaRAS). Secondary Infection: Less common, but ulcers can become secondarily infected by oral flora.
Serious	Scarring: Major RAS can lead to permanent scars and deformation of the oral mucosa due to deep tissue destruction. Systemic Disease Diagnosis: Failure to recognize aphthous-like ulcers as the first manifestation of a serious underlying condition (e.g., Behcet disease, HIV).
Long-term	Chronic pain and reduced quality of life due to frequent recurrence.

Prognosis

Factor	Detail
Factors	Good Prognosis: Minor RAS typically resolves spontaneously within 2 weeks without sequelae. Poor Prognosis: Major RAS often lasts longer, causes significant morbidity, and may result in scarring. Frequency of recurrence can be lifelong, though often decreases with age.
Survival	$\text{RAS}$ itself is not associated with mortality.
Quality of Life	Significantly affected, especially in severe or frequent cases, due to pain, nutritional deficits, and psychological stress.

---

Prevention

Strategy	Recommendation
Primary	Trauma Avoidance: Use a soft toothbrush. Dietary Modification: Identify and eliminate specific food triggers (e.g., chocolate, coffee, cheese, nuts, sharp/crusty breads, highly acidic fruits). SLS Avoidance: Switch to toothpaste free of Sodium Lauryl Sulfate. Stress Management: Implement consistent stress-reduction techniques.
Secondary	Early identification of prodromal symptoms followed by immediate application of topical corticosteroids or barriers to abort the outbreak.
Tertiary	Aggressive management of Major RAS to prevent scarring and long-term functional impairment.

Special Populations

Population	Management Considerations
Pediatric	Diagnosis: Often challenging due to non-specific symptoms. Always rule out HSV gingivostomatitis (RAS does not include vesicles on keratinized tissue). Treatment: Focus on topical measures. Use topical anesthetics 10–15 minutes before meals. Avoid systemic agents unless severe or associated with suspicion of systemic disease.
Geriatric	Often less frequent recurrence than in younger adults. Be mindful of potential drug interactions and systemic comorbidities when initiating systemic treatments. Nutritional deficiencies are more common and should be aggressively screened for. Ensure ulcers are not due to ill-fitting dentures.
Pregnancy	Most topical agents (e.g., lidocaine, topical steroids) are considered safe (Category $\text{B}$ or $\text{C}$). Systemic Agents: Systemic corticosteroids should be used judiciously. Thalidomide is absolutely contraindicated (Category $\text{X}$). Colchicine is generally avoided unless the risk of Behcet disease is high.
Comorbidities	IBD/Celiac: Management of the underlying GI condition often reduces RAS severity. Behcet Disease: Requires high-level immunosuppression, often including corticosteroids, colchicine, thalidomide, or biologics ($\text{TNF}-\alpha$ inhibitors). HIV/AIDS: Severe RAS frequently requires systemic therapy like Thalidomide.

---

Clinical Pearls

Category	Key Insight
Diagnostic	Rule of Thumb: Aphthous ulcers occur only on non-keratinized, moveable mucosa. Look for the classic red halo and yellow/gray center. Crucial Distinction: Aphthous ulcers are not preceded by vesicles (unlike HSV). Lack of systemic symptoms and presence of recurrence confirm the diagnosis of simple RAS.
Treatment	Topical Steroids: Effective only if applied early and directly to the lesion using a dental adhesive paste to maintain contact. Prophylaxis: For patients with clear nutritional deficiencies, chronic supplementation (e.g., $\text{B}_{12}$ $1000 \mu \text{g}$ daily) may prevent recurrence.
Pitfalls	Misdiagnosis: Confusing $\text{MaRAS}$ with oral carcinoma (must biopsy non-healing lesions $>3$ weeks) or confusing $\text{HuRAS}$ with herpes simplex infection. Overtreatment: Do not initiate systemic immunosuppression for mild, infrequent RAS.

Recent Updates

Category	Summary
Guidelines	Current guidelines largely uphold topical high-potency corticosteroids as the initial treatment for inflammation. Growing emphasis on identifying nutritional deficiencies and excluding systemic disease for refractory cases.
Evidence	Emerging evidence supports a role for novel topical agents, including amlexanox $5\%$ oral paste, which may accelerate healing by inhibiting mast cells and $\text{LKT}$ synthesis. Low-level laser therapy (LLLT) has shown promise in reducing pain and recurrence, though standardization is lacking.
Controversies	The role of routine nutritional screening is debated. While deficiencies (Iron, $\text{B}_{12}$) are common, a definitive causal link is not established for all patients with RAS; thus, targeted screening for severe/atypical cases is generally recommended over universal screening.

Key References

• Scully C, Porter S. Oral Mucosal Disease: Recurrent Aphthous Stomatitis. Br J Oral Maxillofac Surg. 2008.
• Pre-Clinical and Clinical Evaluation of Topical and Systemic Agents for RAS (Specific trials on Thalidomide and Colchicine efficacy).
• National Institute of Dental and Craniofacial Research (NIDCR) Consensus on Oral Ulcer Management.
• American Academy of Dermatology (AAD) Guidelines on Mucocutaneous Manifestations of Behcet Disease.

---

MEDICAL DISCLAIMER

This information is provided for educational and informational purposes only and is not a substitute for professional clinical judgment, diagnosis, or treatment. Clinicians must exercise independent judgment, considering the specific circumstances of each patient, before making healthcare decisions. Always consult current, full clinical guidelines and authoritative medical sources.